中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2015年
13期
63-63,65
,共2页
红细胞%地中海贫血%非溶血性发热
紅細胞%地中海貧血%非溶血性髮熱
홍세포%지중해빈혈%비용혈성발열
Red blood cells%Thalassemia patients%Non hemolytic febrile
目的:探讨去白添加剂红细胞与红细胞悬液在地中海贫血患者输注中发生输血不良反应几率。方法:2003年1月-2013年12月收治20例β型地中海贫血患者150份输注去白添加剂红细胞输血病历与150份输注红细胞悬液的输血病历进行比较,分析临床输血不良反应发生原因。结果:150份病历中地中海贫血患者输注去除白细胞添加剂红细胞352次出现输血不良反应率0%,输注红细胞悬液不良反应率10.2%,经过分析得出,差异具有统计学意义(P<0.05)。结论:有效去除白细胞,可以提升输血质量,对降低地中海贫血患者的输血不良反应有重要影响。
目的:探討去白添加劑紅細胞與紅細胞懸液在地中海貧血患者輸註中髮生輸血不良反應幾率。方法:2003年1月-2013年12月收治20例β型地中海貧血患者150份輸註去白添加劑紅細胞輸血病歷與150份輸註紅細胞懸液的輸血病歷進行比較,分析臨床輸血不良反應髮生原因。結果:150份病歷中地中海貧血患者輸註去除白細胞添加劑紅細胞352次齣現輸血不良反應率0%,輸註紅細胞懸液不良反應率10.2%,經過分析得齣,差異具有統計學意義(P<0.05)。結論:有效去除白細胞,可以提升輸血質量,對降低地中海貧血患者的輸血不良反應有重要影響。
목적:탐토거백첨가제홍세포여홍세포현액재지중해빈혈환자수주중발생수혈불량반응궤솔。방법:2003년1월-2013년12월수치20례β형지중해빈혈환자150빈수주거백첨가제홍세포수혈병력여150빈수주홍세포현액적수혈병력진행비교,분석림상수혈불량반응발생원인。결과:150빈병력중지중해빈혈환자수주거제백세포첨가제홍세포352차출현수혈불량반응솔0%,수주홍세포현액불량반응솔10.2%,경과분석득출,차이구유통계학의의(P<0.05)。결론:유효거제백세포,가이제승수혈질량,대강저지중해빈혈환자적수혈불량반응유중요영향。
Objective:To investigate the probability of adverse transfusion reaction of without white additive red blood cells and red blood cell suspension in thalassemia patients infusion. Methods:20 cases of beta thalassemia patients were selected from January 2003 to December 2013.We compared 150 infusion to without white additive red blood cell transfusion records with 150 copies of transfused red blood cells transfusion medical records.We analyzed the causes of clinical blood transfusion adverse reactions before and after the without white additive red blood cells infusion.Results:In 150 cases of medical records of thalassemia patients with the without white additive red blood cells infusion 352 times,the adverse reaction rate of blood transfusion was 0,and the adverse reaction rate of the red blood cell suspension transfusion was 10.2%.After the analysis,the difference was statistically significant(P<0.05).Conclusion:Removal of white cells effectively can enhance the quality of blood transfusion,and it has important effects on reducing blood transfusion adverse reactions in patients with thalassemia.